Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Jennifer Diamond

Concepts (284)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
191
6.660
Why?
Breast Neoplasms
23
2023
2132
4.380
Why?
Immunoconjugates
7
2023
101
2.600
Why?
Antineoplastic Agents
23
2023
2051
2.600
Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
1559
2.460
Why?
Pyrimidines
9
2021
445
2.400
Why?
Receptor, ErbB-2
11
2023
325
1.950
Why?
Protein Kinase Inhibitors
10
2022
872
1.730
Why?
Piperazines
4
2020
336
1.700
Why?
Paclitaxel
6
2022
214
1.620
Why?
Camptothecin
9
2023
106
1.600
Why?
Neoplasms
14
2022
2464
1.600
Why?
Pyrazoles
6
2021
404
1.390
Why?
Quinoxalines
2
2020
65
1.310
Why?
Antibodies, Monoclonal, Humanized
10
2024
755
1.290
Why?
Azepines
3
2020
88
1.250
Why?
Ovarian Neoplasms
4
2020
488
1.220
Why?
Histone Deacetylase Inhibitors
4
2024
207
1.210
Why?
Cyclin-Dependent Kinase 4
2
2018
42
1.110
Why?
Cyclin-Dependent Kinase 6
2
2018
39
1.100
Why?
Neutropenia
4
2022
134
0.890
Why?
Gene Expression Regulation, Neoplastic
5
2020
1351
0.790
Why?
Xenograft Model Antitumor Assays
11
2021
814
0.760
Why?
beta Catenin
2
2020
219
0.760
Why?
Breast Neoplasms, Male
2
2018
29
0.740
Why?
Female
49
2024
68154
0.700
Why?
Cancer Care Facilities
1
2020
32
0.690
Why?
Chemotherapy, Adjuvant
4
2023
376
0.690
Why?
Maximum Tolerated Dose
9
2022
192
0.690
Why?
Benzoxazoles
1
2020
19
0.690
Why?
Receptors, Estrogen
3
2021
424
0.680
Why?
Carcinoma, Lobular
2
2018
48
0.680
Why?
eIF-2 Kinase
1
2019
29
0.650
Why?
Lymphocytes, Tumor-Infiltrating
2
2020
210
0.640
Why?
Tumor Microenvironment
4
2024
623
0.630
Why?
Anthracyclines
3
2023
46
0.610
Why?
Humans
62
2024
128418
0.610
Why?
Taxoids
3
2023
95
0.600
Why?
Drug Resistance, Neoplasm
4
2020
749
0.580
Why?
Wnt Signaling Pathway
1
2019
165
0.580
Why?
Carcinoma, Ductal, Breast
1
2018
82
0.570
Why?
Aurora Kinase A
4
2020
55
0.570
Why?
Aged
22
2023
21953
0.560
Why?
Trastuzumab
4
2023
100
0.560
Why?
Pyrazines
2
2018
86
0.540
Why?
Myocardial Infarction
1
2023
1015
0.520
Why?
Colonic Neoplasms
1
2018
242
0.510
Why?
Pyridines
2
2018
475
0.510
Why?
Tumor Suppressor Protein p53
4
2024
508
0.500
Why?
Neoadjuvant Therapy
1
2018
381
0.490
Why?
Nuclear Proteins
2
2023
657
0.490
Why?
Angiopoietin-1
1
2015
11
0.490
Why?
Angiopoietin-2
1
2015
15
0.490
Why?
Medicare
4
2023
715
0.450
Why?
Uterine Cervical Neoplasms
1
2017
232
0.450
Why?
Cell Line, Tumor
9
2022
3184
0.440
Why?
Colorectal Neoplasms
5
2022
746
0.430
Why?
Middle Aged
23
2021
30889
0.420
Why?
Antibodies, Monoclonal
4
2024
1355
0.410
Why?
Dose-Response Relationship, Drug
6
2022
1936
0.410
Why?
Cell Proliferation
8
2020
2344
0.400
Why?
Tumor Suppressor Proteins
1
2015
313
0.400
Why?
Proto-Oncogene Proteins c-met
1
2013
74
0.400
Why?
Antineoplastic Agents, Immunological
3
2019
175
0.400
Why?
Recombinant Fusion Proteins
1
2015
634
0.390
Why?
Point Mutation
1
2013
223
0.390
Why?
Adult
24
2024
35300
0.390
Why?
Treatment Outcome
12
2022
10152
0.390
Why?
Triazoles
1
2013
147
0.380
Why?
Angiogenesis Inhibitors
3
2018
215
0.370
Why?
Mice, Nude
6
2020
682
0.360
Why?
Carcinoma, Renal Cell
1
2013
179
0.360
Why?
Mitochondria
1
2017
848
0.350
Why?
Clinical Trials, Phase I as Topic
2
2020
50
0.350
Why?
Neoplasm Recurrence, Local
4
2021
958
0.340
Why?
Heart Failure
1
2023
2145
0.340
Why?
Histones
3
2023
586
0.340
Why?
Neoplasm Metastasis
4
2020
608
0.340
Why?
Genes, BRCA2
1
2009
24
0.330
Why?
Genes, BRCA1
1
2009
32
0.330
Why?
Biomarkers, Tumor
2
2014
1181
0.330
Why?
Molecular Targeted Therapy
3
2019
385
0.320
Why?
Aged, 80 and over
8
2020
7033
0.320
Why?
BRCA2 Protein
1
2009
53
0.320
Why?
Thrombophilia
1
2009
66
0.310
Why?
Pregnancy Complications, Neoplastic
1
2009
52
0.310
Why?
Neoplasm Staging
5
2021
1290
0.310
Why?
Lung Neoplasms
2
2024
2328
0.310
Why?
Kidney Neoplasms
1
2013
349
0.310
Why?
Apoptosis
7
2024
2435
0.310
Why?
Quinolines
2
2021
153
0.300
Why?
Aromatase Inhibitors
2
2018
51
0.300
Why?
Receptors, Progesterone
2
2021
341
0.290
Why?
DNA-Binding Proteins
1
2015
1421
0.280
Why?
Mice
9
2021
16602
0.270
Why?
Models, Biological
1
2014
1691
0.260
Why?
Doxorubicin
3
2024
322
0.250
Why?
Liver Neoplasms
1
2009
633
0.220
Why?
Cyclophosphamide
2
2018
227
0.220
Why?
Radiosurgery
2
2019
318
0.220
Why?
Disease Models, Animal
3
2021
3937
0.220
Why?
United States
5
2023
13830
0.210
Why?
Animals
11
2021
34479
0.200
Why?
Cyclin-Dependent Kinase 9
1
2022
10
0.200
Why?
Biopsy
2
2018
1081
0.200
Why?
Histone Deacetylase 1
1
2022
24
0.190
Why?
Administration, Oral
3
2022
754
0.190
Why?
Aurora Kinases
2
2012
29
0.190
Why?
G2 Phase Cell Cycle Checkpoints
3
2022
45
0.190
Why?
Disease Progression
4
2019
2602
0.190
Why?
Topoisomerase I Inhibitors
2
2022
16
0.190
Why?
Fluorouracil
1
2022
197
0.190
Why?
Acetylation
1
2022
237
0.180
Why?
Biliary Tract Neoplasms
1
2021
25
0.180
Why?
Arrhythmias, Cardiac
1
2023
316
0.180
Why?
Androstadienes
1
2021
106
0.180
Why?
Diarrhea
2
2019
177
0.180
Why?
Carboplatin
1
2021
140
0.180
Why?
Heterografts
1
2021
129
0.180
Why?
Necrosis
2
2019
229
0.170
Why?
Drug Administration Schedule
3
2017
751
0.170
Why?
Hospitals, University
1
2021
176
0.170
Why?
Fatigue
2
2022
317
0.170
Why?
Immunotherapy
2
2023
587
0.170
Why?
Histone Deacetylases
1
2022
210
0.170
Why?
Clinical Trials as Topic
3
2016
993
0.170
Why?
Male
13
2021
62858
0.170
Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
58
0.170
Why?
Benzodiazepines
1
2021
129
0.170
Why?
Immune System
1
2021
176
0.160
Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
115
0.160
Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
43
0.160
Why?
Kaplan-Meier Estimate
1
2021
853
0.160
Why?
Tumor Cells, Cultured
1
2020
930
0.150
Why?
Albumins
1
2019
101
0.150
Why?
Maintenance Chemotherapy
1
2018
22
0.150
Why?
Aquaporin 4
1
2019
96
0.150
Why?
Vascular Endothelial Growth Factor A
2
2018
500
0.150
Why?
Aminopyridines
1
2018
96
0.150
Why?
Nausea
1
2018
107
0.150
Why?
Antibodies, Bispecific
1
2018
49
0.140
Why?
Mice, Inbred BALB C
1
2020
1228
0.140
Why?
Drug Therapy, Combination
1
2020
1009
0.140
Why?
Breast
1
2018
152
0.140
Why?
Radiotherapy, Adjuvant
1
2018
209
0.140
Why?
Purines
1
2018
169
0.140
Why?
Benzimidazoles
1
2018
157
0.140
Why?
Mastectomy
1
2018
131
0.140
Why?
Imidazoles
1
2018
226
0.140
Why?
Topotecan
1
2017
12
0.140
Why?
Isoflavones
1
2017
25
0.140
Why?
Calcium-Binding Proteins
1
2018
210
0.140
Why?
Survival Analysis
1
2020
1263
0.140
Why?
Carbolines
1
2017
27
0.140
Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
19
0.140
Why?
Programmed Cell Death 1 Receptor
1
2019
228
0.130
Why?
Inhibitory Concentration 50
2
2016
81
0.130
Why?
Nanoparticles
1
2021
368
0.130
Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
Why?
Cell Survival
1
2019
1077
0.130
Why?
Insulin-Like Growth Factor I
1
2018
307
0.130
Why?
Hypertension
2
2018
1235
0.130
Why?
GPI-Linked Proteins
1
2016
67
0.130
Why?
Adaptor Proteins, Signal Transducing
1
2018
391
0.120
Why?
Neoplasms, Second Primary
1
2016
108
0.120
Why?
Tumor Protein p73
1
2015
14
0.120
Why?
Antibodies, Neoplasm
1
2015
35
0.120
Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1045
0.120
Why?
Phosphorylation
1
2019
1681
0.120
Why?
Risk Reduction Behavior
1
2016
209
0.120
Why?
Hodgkin Disease
1
2016
134
0.120
Why?
Retrospective Studies
3
2021
14454
0.120
Why?
Maytansine
1
2014
16
0.110
Why?
Demography
1
2015
277
0.110
Why?
Brain Edema
1
2014
60
0.110
Why?
Drug Interactions
1
2015
357
0.110
Why?
Survival Rate
2
2019
1869
0.110
Why?
Protein Kinases
1
2015
309
0.110
Why?
Randomized Controlled Trials as Topic
1
2019
1356
0.110
Why?
Sulfones
1
2014
108
0.110
Why?
Threonine
1
2013
44
0.110
Why?
Drug Evaluation, Preclinical
1
2013
168
0.100
Why?
Glycine
1
2014
164
0.100
Why?
Analgesics, Opioid
1
2021
887
0.100
Why?
Tumor Stem Cell Assay
1
2012
32
0.100
Why?
Time Factors
2
2020
6482
0.100
Why?
Drug Design
1
2013
154
0.100
Why?
Methionine
1
2013
157
0.100
Why?
Heterozygote
1
2013
267
0.100
Why?
Disease-Free Survival
1
2014
647
0.100
Why?
Treatment Failure
1
2013
339
0.100
Why?
In Situ Hybridization, Fluorescence
1
2013
313
0.100
Why?
Neovascularization, Pathologic
1
2013
290
0.090
Why?
Computational Biology
1
2015
598
0.090
Why?
Cluster Analysis
1
2012
478
0.090
Why?
Cell Transformation, Neoplastic
1
2013
325
0.090
Why?
Risk Assessment
1
2020
3232
0.090
Why?
Receptor Protein-Tyrosine Kinases
1
2013
221
0.090
Why?
Carcinoma in Situ
1
2011
45
0.090
Why?
Cellular Senescence
1
2012
173
0.090
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
81
0.090
Why?
Colorado
1
2020
4375
0.090
Why?
Mutation
2
2012
3689
0.080
Why?
Sequence Analysis, DNA
1
2013
771
0.080
Why?
Tumor Burden
1
2010
283
0.080
Why?
Brain Neoplasms
2
2019
1163
0.080
Why?
Pregnancy Trimester, Second
1
2009
78
0.080
Why?
Keratinocytes
1
2010
243
0.080
Why?
Mastectomy, Segmental
1
2009
85
0.080
Why?
Pregnancy Trimester, First
1
2009
138
0.080
Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
90
0.080
Why?
Apoptosis Regulatory Proteins
1
2009
182
0.080
Why?
Lymph Node Excision
1
2009
165
0.070
Why?
Risk
1
2009
853
0.070
Why?
Infusions, Intravenous
2
2019
385
0.070
Why?
Cell Adhesion Molecules
2
2019
172
0.070
Why?
Risk Factors
1
2020
9704
0.070
Why?
Prognosis
2
2018
3772
0.070
Why?
Gene Expression Profiling
1
2012
1688
0.060
Why?
Cell Cycle Proteins
2
2023
577
0.060
Why?
Antigens, Neoplasm
2
2019
309
0.060
Why?
CD8-Positive T-Lymphocytes
2
2023
846
0.060
Why?
Cell Cycle
2
2018
581
0.060
Why?
Combined Modality Therapy
2
2019
1204
0.050
Why?
Mesylates
1
2022
7
0.050
Why?
Signal Transduction
2
2014
4826
0.050
Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
64
0.050
Why?
Clinical Protocols
1
2023
252
0.050
Why?
Ligands
1
2024
614
0.050
Why?
RNA, Small Interfering
1
2024
571
0.050
Why?
Chimerism
1
2021
29
0.050
Why?
Lymphoid Tissue
1
2021
68
0.040
Why?
Lymphocyte Subsets
1
2021
85
0.040
Why?
Liver
1
2009
1826
0.040
Why?
Mice, SCID
1
2021
350
0.040
Why?
SEER Program
1
2021
206
0.040
Why?
Hormones
1
2020
140
0.040
Why?
Mice, Inbred NOD
1
2021
586
0.040
Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
Why?
Tissue Distribution
1
2018
291
0.040
Why?
Infant, Newborn
1
2009
5687
0.040
Why?
Anemia
1
2019
160
0.040
Why?
Pregnancy
1
2009
6357
0.030
Why?
Cetuximab
1
2016
93
0.030
Why?
Retreatment
1
2016
69
0.030
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
114
0.030
Why?
Neoplasm Transplantation
1
2016
258
0.030
Why?
Drug Screening Assays, Antitumor
1
2016
195
0.030
Why?
Platinum
1
2016
44
0.030
Why?
Hematopoietic Stem Cell Transplantation
1
2021
572
0.030
Why?
Transcription Factors
1
2023
1628
0.030
Why?
History, Ancient
1
2015
52
0.030
Why?
Proto-Oncogene Proteins p21(ras)
1
2016
258
0.030
Why?
Databases, Genetic
1
2015
228
0.030
Why?
DNA Damage
1
2017
364
0.030
Why?
Mice, Knockout
1
2021
2755
0.030
Why?
Biomarkers
2
2016
3880
0.030
Why?
Opioid-Related Disorders
1
2021
480
0.030
Why?
Phenotype
1
2021
3044
0.020
Why?
Drug Combinations
1
2013
323
0.020
Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
253
0.020
Why?
Intracellular Signaling Peptides and Proteins
1
2015
431
0.020
Why?
Immunohistochemistry
1
2016
1664
0.020
Why?
Biopsy, Needle
1
2011
188
0.020
Why?
Cohort Studies
1
2021
5388
0.020
Why?
Enzyme Inhibitors
1
2014
809
0.020
Why?
Transcription, Genetic
1
2017
1404
0.020
Why?
HT29 Cells
1
2010
36
0.020
Why?
Proto-Oncogene Proteins
1
2014
634
0.020
Why?
ErbB Receptors
1
2013
601
0.020
Why?
Protein-Tyrosine Kinases
1
2013
430
0.020
Why?
Ki-67 Antigen
1
2010
107
0.020
Why?
Patient Selection
1
2013
663
0.020
Why?
Capillary Permeability
1
2010
131
0.020
Why?
Follow-Up Studies
1
2018
4892
0.020
Why?
Patient Satisfaction
1
2013
641
0.020
Why?
Membrane Proteins
1
2015
1105
0.020
Why?
Positron-Emission Tomography
1
2010
283
0.020
Why?
Algorithms
1
2015
1618
0.020
Why?
Magnetic Resonance Imaging
1
2019
3376
0.020
Why?
Tomography, X-Ray Computed
1
2016
2523
0.020
Why?
Adolescent
1
2024
20179
0.010
Why?
Brain
1
2014
2620
0.010
Why?
Young Adult
1
2014
12312
0.010
Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)